The ADAS Biotechnology business is comprised of a team of highly experienced scientists working in collaboration with experts at the University of Nottingham School of Veterinary Medicine and science.

We deliver innovative solutions to diagnostic issues for a range of clients via development of bespoke diagnostic tests for diseases, pathogens, other biological markers and contaminants and are also able to develop methodology for routine testing or screening purposes.

Our business is run as two distinct strands.

Contact details

Development and delivery of molecular diagnostic services

We have developed a range of molecular diagnostic services for a range of clients:

  • eDNA (environmental DNA) diagnostics for detection of invasive, protected, at-risk or species such as the GCN and other aquatic species both by rtPCR and metabarcoding approaches.
  • Detection of soil pests
  • Speciation of animals by DNA sequence analysis (Bats and others)
  • Development of novel PCR based tests and isothermal DNA amplification techniques (LAMP)

Research into novel immuno-diagnostics and therapeutics

Current research interests include:

  • Novel phage display methods for peptide/antibody isolation, based around ‘next generation phage display’ techniques:
    •  Novel phage display library construction
    •  Epitope mapping of antibody based immune responses for the development of novel sero-diagnostics (infectious disease and autoantibodies)
    •  Reverse vaccinology approaches to vaccine antigen discovery
    •  Biomarker discovery
    •  Novel methods for antimicrobial peptide isolation
  • Immunoassay development (ELISA, Western blot) for a range of analytes
  • Prion diseases or transmissible spongiform encephalopathies (TSEs) of livestock (long standing research into the dissemination, environmental fate, strain typing, pre-mortem diagnostics and in-vitro replication of ruminant prions)
  • Monoclonal antibody isolation
  • Recombinant protein production

For more information or to enquire about how we can help you, contact Managing Director Ben Maddison.